We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+5.97%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$194M
AUM Growth
+$4.56M
Cap. Flow
+$124K
Cap. Flow %
0.06%
Top 10 Hldgs %
92.1%
Holding
47
New
6
Increased
8
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$1.44M
2
CFRX
ContraFect Corporation
CFRX
+$485K
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$463K
4
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$360K
5
XLRN
Acceleron Pharma
XLRN
+$347K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.91M
2
NXTM
NxStage Medical Inc.
NXTM
+$857K
3
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$727K
4
ADXS
Advaxis Inc
ADXS
+$231K
5
OPK icon
Opko Health
OPK
+$159K

Sector Composition

Rank Sector Weight
1 Healthcare 96.21%
2 Energy 2.46%
3 Industrials 0.44%
4 Consumer Staples 0.37%
5 Consumer Discretionary 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
26
DELISTED
Clovis Oncology, Inc.
CLVS
$412K 0.21%
5,000
-2,000
-29% -$159K
CMTA
27
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$372K 0.19%
+22,000
New +$360K
BIIB icon
28
Biogen
BIIB
$29.5B
$313K 0.16%
1,000
– –
QTNT
29
DELISTED
Quotient Limited Ordinary Shares
QTNT
$294K 0.15%
1,493
-500
-25% -$99.8K
XNCR icon
30
Xencor
XNCR
$1.39B
$282K 0.15%
12,300
– –
DRNA
31
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$259K 0.13%
45,000
+25,000
+125% +$91K
ICPT
32
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$250K 0.13%
+4,300
New +$463K
PRTA icon
33
Prothena Corp
PRTA
$454M
$235K 0.12%
+3,632
New +$222K
GNMX
34
DELISTED
Aevi Genomic Medicine Inc
GNMX
$161K 0.08%
128,000
– –
FOLD
35
DELISTED
Amicus Therapeutics
FOLD
$151K 0.08%
+10,000
New +$132K
CYTK icon
36
Cytokinetics
CYTK
$10.7B
$145K 0.07%
+10,000
New +$137K
WKHS icon
37
Workhorse Group
WKHS
$30.1M
$138K 0.07%
17
– –
OMED
38
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$130K 0.07%
28,689
– –
GNCA
39
DELISTED
Genocea Biosciences, Inc.
GNCA
$57K 0.03%
4,875
– –
OPK icon
40
Opko Health
OPK
$906M
– –
-24,158
Closed -$159K
PACB icon
41
Pacific Biosciences
PACB
$422M
– –
-27,000
Closed -$96K
PRTK
42
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-30,150
Closed -$727K
ADXS
43
DELISTED
Advaxis Inc
ADXS
– –
-2,373
Closed -$231K
NXTM
44
DELISTED
NxStage Medical Inc.
NXTM
– –
-34,200
Closed -$857K
MACK
45
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-5,592
Closed -$55K
ROKA
46
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
– –
-46,731
Closed -$121K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Birchview Capital held 47 positions worth $194M, up 2.4% from $189M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Birchview Capital's Q3 2017 filing shows 6 new, 8 increased, 4 reduced and 7 closed positions. Its largest new stake was Intercept Pharmaceuticals, Inc.: 4,300 shares worth $250K. The largest sale was Celgene Corp, an estimated $1.91M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Industrials.

  • Birchview Capital's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 4,300 shares worth $250K.
  • Birchview Capital added most to Neurocrine Biosciences in Q3 2017, an estimated $1.44M increase.
  • Birchview Capital's biggest Q3 2017 reduction was Celgene Corp, cutting an estimated $1.91M.
  • Birchview Capital fully exited NxStage Medical Inc. in Q3 2017, selling an estimated $857K.
  • Birchview Capital's ten largest holdings make up 92% of its $194M portfolio in Q3 2017.
  • Birchview Capital opened 6 new positions and closed 7 in Q3 2017.
  • Birchview Capital's portfolio value rose 2.4% quarter-over-quarter to $194M.

Based on Birchview Capital's 13F filing for Q3 2017, filed 2 Nov 2017.